Logo image of CYCC

CYCLACEL PHARMACEUTICALS INC (CYCC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CYCC - US23254L8019 - Common Stock

6.365 USD
-0.4 (-5.98%)
Last: 9/11/2025, 8:00:01 PM
6.4 USD
+0.04 (+0.55%)
After Hours: 9/11/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, CYCC scores 3 out of 10 in our fundamental rating. CYCC was compared to 531 industry peers in the Biotechnology industry. The financial health of CYCC is average, but there are quite some concerns on its profitability. CYCC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CYCC had negative earnings in the past year.
In the past year CYCC has reported a negative cash flow from operations.
CYCC had negative earnings in each of the past 5 years.
In the past 5 years CYCC always reported negative operating cash flow.
CYCC Yearly Net Income VS EBIT VS OCF VS FCFCYCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

CYCC has a worse Return On Assets (-146.06%) than 84.29% of its industry peers.
The Return On Equity of CYCC (-177.03%) is worse than 64.88% of its industry peers.
Industry RankSector Rank
ROA -146.06%
ROE -177.03%
ROIC N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYCC Yearly ROA, ROE, ROICCYCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CYCC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYCC Yearly Profit, Operating, Gross MarginsCYCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

6

2. Health

2.1 Basic Checks

CYCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYCC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CYCC has been increased compared to 5 years ago.
There is no outstanding debt for CYCC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CYCC Yearly Shares OutstandingCYCC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
CYCC Yearly Total Debt VS Total AssetsCYCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

CYCC has an Altman-Z score of -136.20. This is a bad value and indicates that CYCC is not financially healthy and even has some risk of bankruptcy.
CYCC has a worse Altman-Z score (-136.20) than 96.86% of its industry peers.
CYCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -136.2
ROIC/WACCN/A
WACC9.66%
CYCC Yearly LT Debt VS Equity VS FCFCYCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

A Current Ratio of 5.77 indicates that CYCC has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.77, CYCC is doing good in the industry, outperforming 61.55% of the companies in the same industry.
A Quick Ratio of 5.77 indicates that CYCC has no problem at all paying its short term obligations.
CYCC has a Quick ratio of 5.77. This is in the better half of the industry: CYCC outperforms 61.74% of its industry peers.
Industry RankSector Rank
Current Ratio 5.77
Quick Ratio 5.77
CYCC Yearly Current Assets VS Current LiabilitesCYCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 96.85% over the past year.
The Revenue for CYCC has decreased by -87.50% in the past year. This is quite bad
EPS 1Y (TTM)96.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.43%
Revenue 1Y (TTM)-87.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, CYCC will show a very strong growth in Earnings Per Share. The EPS will grow by 36.35% on average per year.
Based on estimates for the next years, CYCC will show a very strong growth in Revenue. The Revenue will grow by 385.15% on average per year.
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5Y36.35%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5Y385.15%

3.3 Evolution

CYCC Yearly Revenue VS EstimatesCYCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2018 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CYCC Yearly EPS VS EstimatesCYCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -10K -20K -30K -40K -50K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYCC. In the last year negative earnings were reported.
Also next year CYCC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYCC Price Earnings VS Forward Price EarningsCYCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYCC Per share dataCYCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

A more expensive valuation may be justified as CYCC's earnings are expected to grow with 57.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%

More info and screens

0

5. Dividend

5.1 Amount

CYCC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYCLACEL PHARMACEUTICALS INC

NASDAQ:CYCC (9/11/2025, 8:00:01 PM)

After market: 6.4 +0.04 (+0.55%)

6.365

-0.4 (-5.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12
Earnings (Next)11-10 2025-11-10
Inst OwnersN/A
Inst Owner Change-99.7%
Ins OwnersN/A
Ins Owner Change30.43%
Market Cap14.26M
Revenue(TTM)10.00K
Net Income(TTM)-6.43M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.03
Dividend Growth(5Y)-37.21%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-50.98%
Min Revenue beat(4)-100%
Max Revenue beat(4)96.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1425.76
P/FCF N/A
P/OCF N/A
P/B 3.93
P/tB 3.93
EV/EBITDA N/A
EPS(TTM)-122.02
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-3.9
FCFYN/A
OCF(TTM)-3.9
OCFYN/A
SpS0
BVpS1.62
TBVpS1.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -146.06%
ROE -177.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.77
Quick Ratio 5.77
Altman-Z -136.2
F-Score3
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.43%
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5Y36.35%
Revenue 1Y (TTM)-87.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5Y385.15%
EBIT growth 1Y48.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y57.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.04%
OCF growth 3YN/A
OCF growth 5YN/A

CYCLACEL PHARMACEUTICALS INC / CYCC FAQ

What is the fundamental rating for CYCC stock?

ChartMill assigns a fundamental rating of 3 / 10 to CYCC.


What is the valuation status of CYCLACEL PHARMACEUTICALS INC (CYCC) stock?

ChartMill assigns a valuation rating of 1 / 10 to CYCLACEL PHARMACEUTICALS INC (CYCC). This can be considered as Overvalued.


How profitable is CYCLACEL PHARMACEUTICALS INC (CYCC) stock?

CYCLACEL PHARMACEUTICALS INC (CYCC) has a profitability rating of 0 / 10.


How financially healthy is CYCLACEL PHARMACEUTICALS INC?

The financial health rating of CYCLACEL PHARMACEUTICALS INC (CYCC) is 6 / 10.